Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.
Br J Cancer
; 110(12): 2847-54, 2014 Jun 10.
Article
en En
| MEDLINE
| ID: mdl-24832174
ABSTRACT
BACKGROUND:
[(18)F]fluorothymidine (FLT) has been proposed as a positron emission tomography (PET)-imaging biomarker of proliferation for breast cancer. The aim of this prospective study was to assess the feasibility of FLT-PET-CT as a technique for predicting the response to neoadjuvant chemotherapy (NAC) in primary breast cancer and to compare baseline FLT with Ki-67.METHODS:
Twenty women with primary breast cancer had a baseline FLT-PET-CT scan that was repeated before the second cycle of chemotherapy. Expression of Ki-67 in the diagnostic biopsy was quantified. From the FLT-PET-CT scans lesion maximum and mean standardised uptake values (SUVmax, SUVmean) were calculated.RESULTS:
Mean baseline SUVmax was 7.3, and 4.62 post one cycle of NAC, representing a drop of 2.68 (36.3%). There was no significant association between baseline, post chemotherapy, or change in SUVmax and pathological response to NAC. There was a significant correlation between pre-chemotherapy Ki-67 and SUVmax of 0.604 (P=0.006).CONCLUSIONS:
Baseline SUVmax measurements of FLT-PET-CT were significantly related to Ki-67 suggesting that it is a proliferation biomarker. However, in this series neither the baseline value nor the change in SUVmax after one cycle of NAC were able to predict response as most patients had a sizeable SUVmax reduction.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Didesoxinucleósidos
/
Radiofármacos
/
Tomografía de Emisión de Positrones
Tipo de estudio:
Evaluation_studies
/
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Br J Cancer
Año:
2014
Tipo del documento:
Article